| Previous Close | 0.4600 |
| Open | 0.4415 |
| Bid | 0.4420 x 3000 |
| Ask | 0.5100 x 800 |
| Day's Range | 0.4415 - 0.4890 |
| 52 Week Range | 0.4300 - 3.3600 |
| Volume | 45,961 |
| Avg. Volume | 249,103 |
| Market Cap | 18.067M |
| Beta | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9030 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.52 |
LAVAL, QUÉBEC, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the first quarter ending June 30, 2018. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “Our two TRILOGY Phase 3 studies remain on track to complete enrollment this year. “We have nearly completed the manufacturing of all of the clinical trial materials needed for TRILOGY, and have further diversified our supply of raw krill oil by having completed the validation of a new supplier.
The Laval, Quebec-based company said it had a loss of 18 cents per share. The company's shares closed at 47 cents. A year ago, they were trading at $1.33. _____ This story was generated by Automated Insights ...
LAVAL, QUÉBEC, July 31, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced the mailing of its management information circular for the upcoming annual meeting of the shareholders (the “Meeting”) of the Company to be held at 1000 De La Gauchetière Street West, Suite 2100, Montreal, Québec H3B 4W5, Canada, on August 28, 2018 at 10:00 a.m. The Company also announces that, subject to the approval of shareholders at the Meeting, the Board of Directors has amended the Company’s stock option plan (the “Stock Option Plan”) in order to decrease the fixed number of common shares of the Company (“Common Shares”) that may be issued upon the exercise of all options granted under the Stock Option Plan from the previous proposal of 7,325,612 shares, as announced on July 2, 2018, which would have represented 20% of the issued and outstanding Common Shares as of June 27, 2018, to 5,494,209 shares, representing 15% of the issued and outstanding Common Shares as of June 27, 2018.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Protalix Biotherapeutics Inc (NYSE: PLX ) stock gained ...
LAVAL, Québec, July 24, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (ACST) (ACST.V), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) on its composition-of-matter patent application for “Concentrated Therapeutic Phospholipid Compositions.” The patent provides comprehensive coverage over a broad range of concentrated therapeutic phospholipid compositions. Jan D’Alvise, president and CEO of Acasti, commented, “This Notice of Allowance on our composition patent application in the United States is a major milestone as we advance our strategic and partnering discussions. Given our strong intellectual property protection, and the clinical benefits derived from our unique omega-3 phospholipid composition, we firmly believe CaPre has the potential to become best-in-class.
LAVAL, Québec, July 02, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (ACST) (ACST.V), today announced the grant of stock options to its employees, executives and directors, and that it has also elected to issue common shares to the holders of its outstanding convertible debentures in satisfaction of interest payable. The stock options were granted by the Board of Directors as part of the Company’s annual performance review in accordance with the Company’s Long-Term Incentive Program (LTIP).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 27) Aptinyx Inc (NASDAQ: APTX ) Cardiovascular Systems Inc (NASDAQ: ...
LAVAL, Québec, June 27, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (ACST) (ACST.V), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the fourth quarter and fiscal year ending March 31, 2018. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “Fiscal 2018 was a transformative year for the Company, culminating in the initiation of our pivotal Phase 3 program (“TRILOGY”) to demonstrate the effectiveness of CaPre in lowering triglyceride levels (TGs) in patients with severe hypertriglyceridemia (HTG), as well as the potential to improve these patients’ broader lipid profile. If our phase 3 data replicates our phase 2 results, it could position CaPre as best-in-class in the marketplace. I am pleased to report that as of June 26th, 2018 we had reached the 35% enrollment milestone, with 463 patients enrolled, and 41 patients randomized at 110 clinical sites across North America that continue to actively screen and enroll patients.
CaPre was featured in an industry breakfast symposium, entitled “Omega-3, Triglycerides, and CVD: Current Status and Future Directions,” presented by Dr. Harold Bays, an investigator in the Company’s phase 3 TRILOGY clinical trials for CaPre, on June 11, 2018 at 7:00 a.m. to 8:30 a.m. Eastern time. Dr. Bays, MD, FOMA, FTOS, FACC, FACE, FNLA is the Medical Director / President of the Louisville Metabolic and Atherosclerosis Research Center, in Louisville, KY, USA. The breakfast symposium highlighted recent developments in the field of hypertriglyceridemia. Pierre Lemieux, Ph.D., COO and CSO of Acasti Pharma, followed Dr. Bays’ presentation with a brief corporate presentation on Acasti Pharma, including an update on the progress of the phase 3 TRILOGY clinical trials for CaPre.
LAVAL, Québec, June 06, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (ACST) (ACST.V) (the “Company” or “Acasti Pharma”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the Company is scheduled to present at this year’s XVIII th International Symposium on Atherosclerosis (ISA2018), the premier conference for international atherosclerosis research. CaPre will be featured in an industry breakfast symposium, entitled “Omega-3, Triglycerides, and CVD: Current Status and Future Directions,” presented by Dr. Harold Bays, an investigator in the Company’s phase 3 TRILOGY clinical trials for CaPre, on June 11, 2018 at 7:00 a.m. to 8:30 a.m. Eastern time. Dr. Bays, MD, FOMA, FTOS, FACC, FACE, FNLA is the Medical Director / President of the Louisville Metabolic and Atherosclerosis Research Center, in Louisville, KY, USA.
LAVAL, Québec, June 04, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (ACST) (ACST.V) (the “Company” or “Acasti Pharma”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced the appointment of Brian Groch as Chief Commercial Officer. Mr. Groch brings over 25 years of senior experience in the healthcare and life science industries, including product commercialization, developing and executing global sales strategies, business development, and operations.
Acasti Pharma Inc. today announced that the first patient has been randomized in the company's TRILOGY Phase 3 program evaluating lead drug candidate CaPre for the treatment of severe hypertriglyceridemia ...
The Laval, Quebec-based company said it had a loss of 31 cents per share. For the year, the company said its loss was nearly unchanged at $8 million. Annual losses per share dropped to 74 cents from 74 ...
Acasti Pharma Inc. , a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, ...
Acasti Pharma Inc. , a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, ...
Acasti Pharma Inc. , a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, ...
Acasti Pharma Inc. announces that in accordance with the terms of its outstanding convertible debentures in the total aggregate principal amount of $2,000,000 issued on February 21, 2017 , the Corporation ...
Acasti Pharma Inc. , an emerging biopharmaceutical company focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, ...